Coformulated Bictegravir, Emtricitabine, And Tenofovir Vs. Dolutegravir With Emtricitabine And Tenofovir For Treatment Of HIV

- Nov 14, 2017 -

Coformulated bictegravir, emtricitabine, and tenofovir vs. dolutegravir with emtricitabine and tenofovir for treatment of HIV


November 06, 2017



Knowing that first-line HIV therapies typically pair an integrase strand transfer inhibitor (INSTI) with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), researchers compared two such combinations to determine if one was better than the other.

Knowing that first-line HIV therapies typically pair an integrase strand transfer inhibitor (INSTI) with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), researchers compared two such combinations to determine if one was better than the other. About 650 adults with previously untreated HIV were recruited for the multinational, Phase III study. All received the NRTIs emtricitabine and tenofovir alafenamide—which, based on randomization, were coformulated with either bictegravir or dolutegravir. The medication, along with matching placebo, was administered once daily. A prespecified target of virological suppression was achieved by 93% of the dolutegravir patients and 89% of the bictegravir patients at 48 weeks, the difference between the two falling short of the noninferiority threshold of -12%. Although it could not claim noninferiority in terms of efficacy, there were fewer drug-related adverse events with bictegravir compared with dolutegravir.



source: pharmacist.com